Dr. Reddy's, Takeda Sign Deal to Distribute QDENGA Dengue Vaccine in India

06:17 AM EDT, 09/18/2026 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) will commercially launch Takeda Pharmaceutical's Qdenga dengue vaccine in India in H1 2027, subject to completion of applicable processes, the companies said Friday. India's Central Drugs Standard Control Organisation approved Qdenga in July for people aged four to 60 years, administered as two doses three months apart, according to the companies. Dr. Reddy's and Takeda will jointly promote and distribute the vaccine and conduct disease-awareness activities, they added. Dr. Reddy's will handle promotion and distribution in the private market, while Takeda will retain rights for the public market as well as ownership and overall medical and brand oversight of the vaccine in India, the companies said. The companies did not disclose the financial terms of the partnership.